These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 18689864

  • 21. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
    Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez MA, Aguiar Morales J.
    Ann Oncol; 2007 Mar; 18(3):556-60. PubMed ID: 17082512
    [Abstract] [Full Text] [Related]

  • 22. [Multiple myeloma].
    Abe M.
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [Abstract] [Full Text] [Related]

  • 23. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
    Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H.
    Breast Cancer Res Treat; 2011 Jun; 127(2):429-38. PubMed ID: 21394500
    [Abstract] [Full Text] [Related]

  • 24. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 25. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
    Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, Wade JL, Fisch MJ, Henry NL, Hershman DL, Gralow J.
    JAMA Oncol; 2021 Feb 01; 7(2):246-254. PubMed ID: 33331905
    [Abstract] [Full Text] [Related]

  • 26. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
    Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E.
    Br J Haematol; 2006 Sep 01; 134(6):620-3. PubMed ID: 16889620
    [Abstract] [Full Text] [Related]

  • 27. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF.
    Ann N Y Acad Sci; 2011 Feb 01; 1218():47-54. PubMed ID: 20946574
    [Abstract] [Full Text] [Related]

  • 28. Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates.
    Uña E.
    BMJ Case Rep; 2012 Mar 27; 2012():. PubMed ID: 22605820
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
    Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE.
    J Clin Oncol; 2013 Jul 20; 31(21):2685-91. PubMed ID: 23796998
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C, Estilo C.
    Oncology (Williston Park); 2006 Aug 20; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
    Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M.
    Leukemia; 2007 Jul 20; 21(7):1545-8. PubMed ID: 17410188
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
    Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN.
    J Bone Miner Res; 2008 Jun 20; 23(6):826-36. PubMed ID: 18558816
    [Abstract] [Full Text] [Related]

  • 39. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
    Eur Urol; 2008 Nov 20; 54(5):1066-72. PubMed ID: 18602738
    [Abstract] [Full Text] [Related]

  • 40. Intravenous bisphosphonate-associated osteonecrosis of the jaw.
    Statz TA, Guthmiller JM, Humbert LA, Johnson GK.
    J Periodontol; 2007 Nov 20; 78(11):2203-8. PubMed ID: 17970689
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.